Display options
Cite
Akinyemiju T, Moore JX, Judd SE, et al. Pre-diagnostic biomarkers of metabolic dysregulation and cancer mortality. Oncotarget. 2018;9(22):16099-16109doi: 10.18632/oncotarget.24559.
Akinyemiju, T., Moore, J. X., Judd, S. E., Pisu, M., Goodman, M., Howard, V. J., Long, L., Safford, M., Gilchrist, S. C., & Cushman, M. (2018). Pre-diagnostic biomarkers of metabolic dysregulation and cancer mortality. Oncotarget, 9(22), 16099-16109. https://doi.org/10.18632/oncotarget.24559
Akinyemiju, Tomi, et al. "Pre-diagnostic biomarkers of metabolic dysregulation and cancer mortality." Oncotarget vol. 9,22 (2018): 16099-16109. doi: https://doi.org/10.18632/oncotarget.24559
Akinyemiju T, Moore JX, Judd SE, Pisu M, Goodman M, Howard VJ, Long L, Safford M, Gilchrist SC, Cushman M. Pre-diagnostic biomarkers of metabolic dysregulation and cancer mortality. Oncotarget. 2018 Feb 23;9(22):16099-16109. doi: 10.18632/oncotarget.24559. eCollection 2018 Mar 23. PMID: 29662629; PMCID: PMC5882320.
Copy Download .nbib Format: NLM
Share it on

Oncotarget. 2018 Feb 23;9(22):16099-16109. doi: 10.18632/oncotarget.24559. eCollection 2018 Mar 23.

Pre-diagnostic biomarkers of metabolic dysregulation and cancer mortality.

Oncotarget

Tomi Akinyemiju, Justin Xavier Moore, Suzanne E Judd, Maria Pisu, Michael Goodman, Virginia J Howard, Leann Long, Monika Safford, Susan C Gilchrist, Mary Cushman

Affiliations

  1. Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, USA.
  2. Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA.
  3. Department of Epidemiology, University of Kentucky, Lexington, KY, USA.
  4. Department of Biostatistics, University of Alabama at Birmingham, Birmingham, AL, USA.
  5. Division of Preventive Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
  6. Department of Epidemiology, Emory University Rollins School of Public Health, Atlanta, GA, USA.
  7. Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
  8. Department of Clinical Cancer Prevention and Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  9. Department of Medicine and Vermont Cancer Center, Larner College of Medicine at the University of Vermont, Burlington, VT, USA.

PMID: 29662629 PMCID: PMC5882320 DOI: 10.18632/oncotarget.24559

Abstract

INTRODUCTION: The obesogenic milieu is a pro-tumorigenic environment that promotes tumor initiation, angiogenesis and metastasis. In this prospective cohort, we examined the association between pre-diagnostic metabolic biomarkers, plasma adiponectin, resistin, leptin and lipoprotein (a), and the risk of cancer mortality.

METHODS: Prospective data was obtained from the REasons for Geographic and Racial Differences in Stroke (REGARDS) cohort of Blacks and Whites followed from 2003 through 2012 for cancer mortality. We determined the association between metabolism biomarkers (log-transformed and tertiles) and risk of cancer mortality using Cox Proportional Hazards models with robust sandwich estimators to calculate the 95% confidence intervals (CIs), and adjusted for baseline covariates, including age, gender, income, education, physical activity, BMI, smoking status, alcohol use, and comorbidity score.

RESULTS: Among 1764 participants with available biomarker data, each SD higher log-leptin was associated with a 54% reduced risk of total cancer mortality (HR: 0.46, 95% CI: 0.23 - 0.92) and obesity-related cancer mortality (HR: 0.55, 95% CI: 0.39-0.79). Among Blacks only, each SD higher log-resistin was associated with a nearly 7-fold increased risk of cancer mortality (adjusted HR: 6.68, 95% CI: 2.10 - 21.21). There were no significant associations of adiponectin or Lp(a) and cancer mortality.

CONCLUSIONS: Leptin is involved in long-term regulation of energy balance, while resistin is involved in chronic inflammation and LDL production. These findings highlight the biological mechanisms linking metabolic dysregulation with cancer mortality, and the influence of resistin on cancer mortality only among Blacks suggests that this hormone may be a useful biomarker of racial differences in cancer mortality that deserves further study.

IMPACT: Our observed increased risk of cancer mortality associated with higher serum resistin levels among Blacks suggests that if validated in larger cohorts, clinical strategies focused on resistin control may be a promising cancer prevention strategy.

Keywords: cancer mortality; metabolic biomarkers; metabolism; racial disparities

Conflict of interest statement

CONFLICTS OF INTEREST None.

References

  1. Stroke. 2014 Jun;45(6):1646-50 - PubMed
  2. Annu Rev Pathol. 2016 May 23;11:421-49 - PubMed
  3. BMJ Open. 2014 Jul 03;4(7):e005245 - PubMed
  4. Neuroepidemiology. 2005;25(3):135-43 - PubMed
  5. Am J Epidemiol. 2011 Jun 1;173(11):1319-26 - PubMed
  6. J Clin Oncol. 2015 Mar 10;33(8):885-93 - PubMed
  7. J Dig Dis. 2011 Aug;12(4):234-44 - PubMed
  8. Curr Obes Rep. 2015 Jun;4(2):241-9 - PubMed
  9. Cancer Prev Res (Phila). 2015 Jun;8(6):545-51 - PubMed
  10. Cancer Prev Res (Phila). 2015 Dec;8(12 ):1138-45 - PubMed
  11. J Clin Oncol. 2014 Nov 1;32(31):3568-74 - PubMed
  12. Clin Biochem. 2017 Jun;50(9):525-528 - PubMed
  13. JAMA Intern Med. 2015 May;175(5):767-76 - PubMed
  14. Asian Pac J Cancer Prev. 2014;15(15):6137-43 - PubMed
  15. J Thromb Haemost. 2014 Apr;12(4):564-70 - PubMed
  16. JAMA. 2012 Nov 7;308(17):1768-74 - PubMed
  17. Oncotarget. 2015 Aug 28;6(25):21100-19 - PubMed
  18. Clin Cancer Res. 2009 May 15;15(10):3256-64 - PubMed
  19. Stroke. 2015 Feb;46(2):322-8 - PubMed
  20. Cell Metab. 2016 Jan 12;23 (1):77-93 - PubMed
  21. Gynecol Oncol. 2012 Jun;125(3):742-50 - PubMed
  22. Lipids Health Dis. 2015 Nov 26;14:154 - PubMed
  23. J Gastroenterol. 2014 Sep;49(9):1342-51 - PubMed
  24. Cancer Med. 2016 Jan;5(1):120-8 - PubMed
  25. J Gastrointestin Liver Dis. 2012 Mar;21(1):23-9 - PubMed
  26. J Clin Oncol. 2011 Jan 1;29(1):32-9 - PubMed
  27. Cancer Causes Control. 2015 Jul;26(7):1047-52 - PubMed
  28. Medicine (Baltimore). 2016 Mar;95(11):e3073 - PubMed
  29. Gynecol Oncol. 2013 May;129(2):353-7 - PubMed
  30. J Cancer Res Ther. 2014 Apr-Jun;10(2):347-53 - PubMed
  31. PLoS One. 2013 Dec 04;8(12):e82460 - PubMed
  32. World J Gastroenterol. 2014 Aug 7;20(29):9759-74 - PubMed

Publication Types

Grant support